Major histocompatibility complex class II – T-cell receptor complex (MHC II-TCR complex)

The Major histocompatibility complex class II – T-cell receptor (MHC II-TCR) complex is a fundamental molecular assembly required for the initiation and regulation of the adaptive immune response. It forms at the immunological synapse between an antigen-presenting cell (APC) and a CD4+ T cell, including regulatory T cells (Tregs), where it facilitates the recognition of exogenous peptides [1]. The complex consists of a polymorphic MHC class II molecule presenting a processed antigenic peptide, which is specifically recognized by the heterodimeric T-cell receptor [2]. In the context of Tregs, this interaction is crucial for maintaining peripheral tolerance and suppressing overactive immune responses [3]. Dysregulation of this complex is central to the pathogenesis of autoimmune diseases, where self-peptides are inappropriately presented, and in cancer, where tumor-driven MHC II expression can modulate the microenvironment [4]. Therapeutic strategies targeting this complex include peptide-based vaccines to induce tolerance, monoclonal antibodies against MHC II or TCR components, and inhibitors of co-receptors like LAG-3 that modulate the interaction [5].

Other names

HLA class II-TCR complexMHCII-TCR interactionCD4-MHC II-TCR complexAntigen-MHC II-TCR synapseMHC class II-peptide-TCR complex

Modulation of T-cell signaling through competitive inhibition of peptide binding, blockade of co-inhibitory receptors like LAG-3, or induction of antigen-specific tolerance.